preladenant   Click here for help

GtoPdb Ligand ID: 5614

Synonyms: SCH-420814 | SCH420814
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Preladenant (SCH 420814) was an adenosine A2A receptor antagonist being developed for Parkinson's disease. Promising Phase 2 trial results did not translate to a significant effect over placebo in Phase 3 trial. Development has been discontinued.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 125
Molecular weight 503.24
XLogP 2.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COCCOc1ccc(cc1)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1
Isomeric SMILES COCCOc1ccc(cc1)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1
InChI InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29)
1. Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. (2013)
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.
Mov. Disord., 28 (6): 817-20. [PMID:23589371]
2. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Lancet Neurol, 10 (3): 221-9. [PMID:21315654]
3. Müller CE, Ferré S. (2007)
Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders.
Recent Pat CNS Drug Discov, 2 (1): 1-21. [PMID:18221214]
4. Szabó N, Kincses ZT, Vécsei L. (2011)
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Expert Opin Drug Metab Toxicol, 7 (4): 441-55. [PMID:21332415]